63 completed, 20 recruiting, 20 unknown, 15 terminated. 62 Phase 2, 35 Phase 1, 23 Phase 3, 14 Not applicable, 6 Early Phase 1.
Follow Epidermolysis Bullosa: new trials by email Literature Review of Epidermolysis Bullosa trials Research Report on Epidermolysis Bullosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%) - Epidermolysis Bullosa (EB) | Phase 3 | Not yet recruiting | Paradigm Therapeutics | 80 | 2026-11-15 | 2026-09-09 |
| Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds Non-conforming pz-cel surgical application to RDEB wounds, Additional biopsies, Pz-cel surgical application to DEB wounds - Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Phase 4 | Not yet recruiting | Abeona Therapeutics, Inc | 100 | 2026-11-01 | 2026-08-06 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa | Phase 2 | Recruiting | Energenesis Biomedical Co., Ltd. | 24 | 2026-10-08 | 2026-10-05 |
| Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex Filsuvez - Epidermolysis Bullosa Simplex | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-10-01 | 2026-08-10 |
| Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions EndoFlip - Dysphagia, Esophageal Stricture | Not applicable | Recruiting | Johns Hopkins University | 25 | 2026-07-24 | 2026-08-24 |
| Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) - Epidermolysis Bullosa (EB) | Phase 3 | Recruiting | Paradigm Therapeutics | 80 | 2026-07-21 | 2026-10-15 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
| Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study) The retrospective data collected will be entered into an eCRF and then analyzed centrally - Recessive Dystrophic Epidermolysis Bullosa, Dysphagia | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 15 | 2026-07-01 | 2026-07-06 |
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study TCP-25 gel, Vehicle (placebo) - Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa | Phase 2 | Recruiting | Xinnate AB | 32 | 2026-01-30 | 2026-11-02 |
| Thera-Clean® Microbubbles System in Patients With Skin Diseases TheraClean - Epidermolysis Bullosa, Ichthyosis | Early Phase 1 | Enrolling by invitation | Northwestern University | 20 | 2026-01-13 | 2026-02-03 |
| Curcumin-Based Photodynamic Therapy in Epidermolysis Bullosa: Wound Healing, Quality of Life, and Salivary Biomarkers Curcumin-based photodynamic therapy - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Dystrophica | Phase 4 | Active not recruiting | Universidade Ceuma | 20 | 2026-01-12 | 2026-07-16 |
| GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) - RDEB, Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | CHU de Quebec-Universite Laval | 9 | 2026-01-07 | 2026-03-18 |
| A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex 5% TolaSure Topical Gel, Topical Placebo Gel - Epidermolysis Bullosa Simplex | Phase 2 | Recruiting | BioMendics, LLC | 40 | 2025-09-11 | 2026-08-13 |
| Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa Immunoglobulin G - Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Recruiting | M. Peter Marinkovich | 8 | 2025-08-04 | 2026-05-05 |
| A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting Prademagene Zamikeracel - Recessive Dystrophic Epidermolysis Bullosa | Recruiting | Abeona Therapeutics, Inc | 250 | 2025-07-25 | 2026-07-14 | |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa KB803, Placebo - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Recruiting | Krystal Biotech, Inc. | 16 | 2025-06-20 | 2026-03-12 |
| Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds two sided debridement pad, one sided debridment pad - Diabetic Ulcers, Arterial Ulcers | Not applicable | Completed | Lohmann & Rauscher | 100 | 2025-05-09 | 2026-09-03 |
| A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa Oleogel-S10 - Epidermolysis Bullosa, Junctional Epidermolysis Bullosa | Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 6 | 2025-04-18 | 2025-12-22 |
| Evaluation of D-Fi for the Treatment of Wounds Due to DEB D-Fi - Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Castle Creek Biosciences, LLC. | 32 | 2025-03-27 | 2026-03-13 |
Showing 20 of 146. Sign in to see all of them.
Epidermolysis Bullosa Dystrophica (77) · Epidermolysis Bullosa Simplex (20) · Epidermolysis Bullosa, Junctional (16) · Skin Diseases (11) · Genetic Diseases, Inborn (7) · Skin Abnormalities (6) · Skin Diseases, Genetic (6) · Ichthyosis (5) · Pruritus (5) · Congenital Abnormalities (4) · Epidermolysis Bullosa Acquisita (4) · Rare Diseases (4) · Blister (3) · Corneal Injuries (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (146) · Skin and Connective Tissue Diseases (145) · Skin Diseases, Vesiculobullous (144) · Congenital Abnormalities (142) · Skin Abnormalities (140) · Skin Diseases, Genetic (140) · Genetic Diseases, Inborn (139) · Skin Diseases (135) · Connective Tissue Diseases (78) · Collagen Diseases (75) · Pathological Conditions, Signs and Symptoms (18) · Nervous System Diseases (9) · Signs and Symptoms (9) · Pathologic Processes (8)
Gentamicins (6) · diacerein (4) · fludarabine (4) · fludarabine phosphate (4) · Busulfan (3) · Cyclophosphamide (3) · Ointments (3) · Antilymphocyte Serum (2) · ON 01910 (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · abobotulinumtoxinA (2) · cyclic adenosine-5'-trimetaphosphate (2) · serlopitant (2) · Alemtuzumab (1)
Centre Hospitalier Universitaire de Nice (9) · Stanford University (9) · Krystal Biotech, Inc. (7) · Abeona Therapeutics, Inc (5) · Assistance Publique - Hôpitaux de Paris (5) · Northwestern University (5) · University of Southern California (5) · Masonic Cancer Center, University of Minnesota (4) · Scioderm, Inc. (4) · Anterogen Co., Ltd. (3) · Castle Creek Biosciences, LLC. (3) · Castle Creek Pharmaceuticals, LLC (3) · National Center for Research Resources (NCRR) (3) · Phoenix Tissue Repair, Inc. (3) · RHEACELL GmbH & Co. KG (3)
United States (76) · France (29) · United Kingdom (13) · Austria (12) · Spain (11) · Germany (10) · Australia (7) · Italy (7) · Poland (7) · Canada (6) · Greece (6) · Israel (6) · Netherlands (5) · Chile (4) · South Korea (4)
Jakub Tolar, MD, PhD (3) · Jean Tang, MD, PhD (3) · Alfred Lane, MD (2) · Alfred T Lane (2) · Antoni Gostynski, MD, PhD (2) · Christine Bodemer, MD, PhD (2) · David Woodley, MD (2) · Elena Pope, MD (2) · Hal Landy, MD (2) · Johann W. Bauer, MD (2) · Joyce M Teng, MD, PhD (2) · Mary Spellman, MD (2) · Matt P Marinkovich, MD (2)
PMID 31541747, PMID 35234826, PMID 19267394, PMID 20466177, PMID 20818854, PMID 21877134, PMID 23483391, PMID 23651789, PMID 25431026, PMID 25832646, PMID 26194911, PMID 26802230, PMID 27015660, PMID 27386970, PMID 27802546, PMID 27940607, PMID 28691931, PMID 28821470, PMID 30843184, PMID 31167965, PMID 31186047, PMID 31215818, PMID 31557321, PMID 31578311, PMID 32576219, PMID 32693833, PMID 32866988, PMID 32939751, PMID 33011075, PMID 33491668, PMID 34665781, PMID 35347281, PMID 35483736, PMID 35964087, PMID 36253825, PMID 36516090, PMID 36813496, PMID 36868990, PMID 39441591, PMID 39627888, PMID 40220208, PMID 40268883, PMID 40570869, PMID 41224305, PMID 41287410, PMID 41327356, PMID 41645556, PMID 42164509, PMID 42205007
2014 (2), 2016 (2), 2017 (2), 2018 (1), 2023 (1), R01AR055914 (1)